Presentation Repository

Investigators of the STAMPEDE study regularly disseminate status updates and results form the study in formal presentations at conferences as well as less formal presentations amongst colleagues or stakeholders to the STAMPEDE trial. Please find the repository of these presentations made with regards to STAMPEDE.

Looking to present any of this information? Then please get in touch with the STAMPEDE trial team and let us know.

Abiraterone acetate plus prednisolone with or without enzalutamide added to androgen deprivation therapy compared to ADT alone for men with high-risk nonmetastatic prostate cancer

Collaborators list

ESMO 2021 - Dr Gert Attard

STAMPEDE Trial Data from ESMO

EMUC 2018 - Prof Nicholas James

Role of Abiraterone Acetate + Prednisolone + ADT in High and Low Risk Metastatic Hormone Naïve Prostate Cancer

ESMO 2018 - Mr Alex Hoyle

Radiotherapy to the primary tumour for men with newly-diagnosed metastatic prostate cancer: Survival results from STAMPEDE

ESMO 2018 - Dr Christopher Parker

Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): long-term survival, quality-adjusted survival and cost-effectiveness analysis.

Genitourinary Cancers Symposium 2018 - Prof Nicholas James